KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2025)

Ginkgo Bioworks Holdings' Current Deferred Revenue history spans 7 years, with the latest figure at $18.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 85.02% year-over-year to $18.9 million; the TTM value through Dec 2025 reached $18.9 million, down 85.02%, while the annual FY2025 figure was $18.9 million, 85.02% down from the prior year.
  • Current Deferred Revenue reached $18.9 million in Q4 2025 per DNA's latest filing, down from $25.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $222.6 million in Q4 2022 to a low of $18.9 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $77.8 million, with a median of $37.2 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: surged 94500.0% in 2021, then crashed 85.02% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $189.2 million in 2021, then increased by 17.65% to $222.6 million in 2022, then dropped by 9.03% to $202.5 million in 2023, then crashed by 37.53% to $126.5 million in 2024, then plummeted by 85.02% to $18.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Current Deferred Revenue are $18.9 million (Q4 2025), $25.2 million (Q3 2025), and $28.3 million (Q2 2025).